Setting new standards in information exchange for the pharmaceutical and biotech industry
Immuno-Oncology Drug Development: Challenges & Next Steps
December 23, 2015
PharmaTalk Radio’s Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what’s currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they address:
- – Ipilumumab/Nivo/Pembro challenges
- – What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
- – Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
- – Blinitumumab
- – The more interesting agents in late stage development now in immunotherapy and its promise
- – Immune related adverse events
- – Adoptive cellular therapies, what is the most promising?
- – Will IO become backbone therapies for cancer?
- – What’s the next set of assets that are going to come out?-
- – What can we expect within the next year or two?
James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline
Listen to the show here: http://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-stepshttp://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-steps
The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.